REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Post-Surgery Recovery Stack

Recovery & Healingintermediate
42
Share
Peptides

3

Avg Daily mcg

2,629

Level

intermediate

Added

May 16, 2026

Overview

The Post-Surgery Recovery Stack is a targeted tissue repair protocol engineered to accelerate healing timelines following surgical procedures. This intermediate-level stack combines three peptides with complementary mechanisms that address wound healing, inflammation management, and tissue remodeling simultaneously. BPC-157, administered at 500mcg twice daily, forms the foundation of this recovery protocol. This 15-amino-acid peptide, originally isolated from human gastric juice, has demonstrated remarkable wound-healing properties in numerous preclinical studies. It accelerates angiogenesis, promotes fibroblast migration to wound sites, and upregulates growth factor receptors including VEGF and EGF. The twice-daily dosing maintains consistent tissue-level concentrations throughout the healing process, supporting continuous repair signaling around the clock. TB-500, dosed at 5000mcg twice weekly, provides the structural scaffolding for tissue regeneration. As a synthetic fragment of Thymosin Beta-4, it promotes cellular migration by upregulating actin polymerization, allowing repair cells to reach damaged tissue more efficiently. TB-500 also reduces scar tissue formation by modulating inflammatory cytokines during the proliferative phase of wound healing, resulting in more functional tissue restoration rather than fibrotic repair. GHK-Cu at 200mcg daily rounds out the stack with its powerful tissue-remodeling properties. This copper-binding tripeptide stimulates collagen synthesis, attracts immune cells for debris clearance, and promotes nerve regeneration. Research has shown GHK-Cu activates over 4,000 genes involved in tissue repair and remodeling, making it an exceptionally broad-spectrum healing agent. This stack is ideal for individuals recovering from orthopedic surgeries, cosmetic procedures, or any operation involving significant tissue disruption. It is recommended to begin the protocol 3-5 days post-surgery once initial hemostasis is established. BPC-157 injections are most effective when administered near the surgical site subcutaneously. A typical cycle runs 6-8 weeks, aligning with standard surgical recovery windows. Bloodwork monitoring is recommended but not strictly required at this intermediate level.

Dosing Protocol

BPC-157

Twice per day

Read more about BPC-157 →

500 mcg

per dose

TB-500

Twice per week

Read more about TB-500 →

5,000 mcg

per dose

200 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.